Dioscin ameliorates diabetes cognitive dysfunction via adjusting P2X7R/NLRP3 signal

Area of Science:

• Pharmacology
• Neuroscience
• Biochemistry

Background:

• Diabetes cognitive dysfunction (DCD) is a growing concern with unclear mechanisms.
• The role of purinergic receptor P2X7 (P2X7R) and NLRP3 inflammasome in DCD requires further elucidation.
• Dioscin's therapeutic potential for DCD is largely unexplored.

Purpose of the Study:

• To investigate the protective effects of dioscin on DCD.
• To elucidate the underlying mechanism involving P2X7R and NLRP3 inflammasome.
• To evaluate dioscin's therapeutic value for DCD.

Main Methods:

• Utilized methylglyoxal-treated PC12 cell and streptozocin-induced rat models for DCD.
• Assessed P2X7R and NLRP3 inflammasome activation in vitro and in vivo.
• Examined the regulatory relationship between P2X7R and NLRP3 inflammasome.
• Investigated the impact of dioscin on these signaling pathways, including overexpression and inhibition studies.

Main Results:

• Dioscin demonstrated a significant protective effect against DCD in both cell and animal models.
• P2X7R and NLRP3 inflammasome signals were found to be activated in DCD.
• P2X7R was shown to regulate NLRP3 inflammasome activity.
• Dioscin's protective effect was associated with the inhibition of the P2X7R/NLRP3 pathway.
• Modulating P2X7R expression altered the efficacy of dioscin's protective effects.

Conclusions:

• Dioscin exerts a protective effect on type 2 diabetes cognitive dysfunction.
• This protection is, at least partially, mediated by the regulation of the P2X7R/NLRP3 signaling pathway.
• Dioscin holds significant therapeutic potential for preventing DCD.